中成药说明书安全性信息项修订的探讨与思考

doi:10.19803/j.1672-8629.20230315

摘要/Abstract

摘要： 目的对中成药说明书安全性信息项如何修订进行探讨与思考。方法参照《已上市中药说明书安全信息项内容修订技术指导原则（试行）》（2022年第1号）,通过分析中成药说明书中【禁忌】【不良反应】【注意事项】【特殊人群用药】及警示语内容,结合中成药说明书安全性信息项修订的实践经验提出相关思考。结果与结论 药品上市许可持有人（简称“持有人”）可从补充安全性信息缺失项内容、规范相关术语、正确标注安全性信息方面对说明书安全性信息项进行完善。在具体修订过程中持有人应通过多个渠道对安全性信息进行全面、系统的检索,将检索到的信息整理、分析,形成证据条目并将其作为修订依据,依据修订依据对中成药说明书安全性信息项进行修订,从而为临床使用中成药提供更加科学准确的指导信息。

关键词: 中成药, 说明书, 安全性信息, 修订, 药品上市许可持有人

Abstract: Objective To study how to revise the safety information items in instructions for traditional Chinese patent medicines and simple preparations. Methods With reference to the Technical Guidelines for the Revision of Safety Information Items in the Instructions of Listed Traditional Chinese Medicine (Trial) (No. 1 in 2022), this paper analyzed the contents of such warnings as “taboos”, “adverse reactions”, “precautions” and “medications for special groups” in the instructions for traditional Chinese patent medicines and simple preparations, and offered recommendations in combination with the practical experience associated with the revision of safety information items in these instructions. Results and Conclusion Marketing authorization holders can improve the safety information items in the instructions by supplementing the missing items, standardizing related terminology, and correctly labeling safety information. During the process of revision, marketing authorization holders are to conduct exhaustive search of safety information by different means, and sort out and analyze the retrieved information as items of evidence that underlie any revision. The safety information items in the instructions for traditional Chinese patent medicines and simple preparations should be revised on this basis so as to provide more accurate guidance for clinical use of traditional Chinese patent medicines and simple preparations.

Key words: Chinese patent drugs, instructions, safety information, revision, marketing authorization holder

中图分类号:

R994.1

雷超, 乔萌, 陈子佳, 张强, 谢雁鸣, 王志飞. 中成药说明书安全性信息项修订的探讨与思考[J]. 中国药物警戒, 2023, 20(12): 1396-1400.

LEI Chao, QIAO Meng, CHEN Zijia, ZHANG Qiang, XIE Yanming, WANG Zhifei. Revision of safety information in instructions of traditional Chinese patent medicines and simple preparations[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1396-1400.

参考文献

[1] ZHOU S, YANG HJ, JING ZW, et al.Analysis of safety information of large varieties of oral traditional Chinese patent medicines and simple preparations instructions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(10): 981-985.
[2] TAO BC, XUE J, ZHOU LF.Labeling of pediatric medication information in injection instructions and risk analysis of pediatric medication[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2020, 26(7): 40-43.
[3] HOU HJ, WANG L, LI XM, et al.Current situation, existing problems and countermeasures of traditional Chinese patent medicines and simple preparations instructions in China[J]. China Food and Drug Administration(中国食品药品监管), 2020(2): 32-39.
[4] LYU XQ, MA MK, ZHU Y, et al.Analysis of safety information and adverse reaction monitoring data of traditional Chinese patent medicines and simple preparations instructions[J]. The Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2019, 36(4): 493-498.
[5] The Bulletin of the State Council of the People’s Republic of China.Measures for the control of poisonous drugs for medical use(医疗用毒性药品管理办法)[EB/OL]. (1988-12-27) [2023-05 -07].https://www.gov.cn/zhengce/2020-12/25/content_5574189.htm.
[6] JIANG H, ZHANG B, ZHANG XM, et al.The evolution and connotation of “taboos and caution” in traditional Chinese medicine[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2022, 28(2): 242-248.
[7] JIANG H, ZHANG XM, ZHANG B, et al.A study on the cognitive status of contraindications of “prohibition”, “avoidance”, and “caution” in clinical application of traditional Chinese medicine[J]. China Pharmacy(中国药房), 2021, 32(3): 358-363.
[8] ZHANG B, ZHANG XM, LIN ZJ, et al.Series of group standards of technical specifications for revision of safety information in marketed Chinese patent medicine instructions[J]. Chin J Chin Mater Med(中国中药杂志), 2022, 47(2): 285-294.
[9] ZHANG B, LIN ZJ, ZHANG XM, et al.Investigation on the current situation of domestic traditional Chinese patent medicines and simple preparations instructions and suggestions for revision and improvement[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2017, 26(8): 561-564.
[10] LIU X, ZHANG B, WANG HN, et al.Thoughts and suggestions on revision and improvement of traditional Chinese patent medicines and simple preparations instruction precautions[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2018, 27(1): 45-49.
[11] ZHANG B, LYU JT, ZHANG XM, et al.Perfect clinical pharmacy service strategy based on traditional Chinese patent medicines and simple preparations instructions “drug use for special groups”[J]. Journal of Beijing University of Traditional Chinese Medicine(北京中医药大学学报), 2022, 45(10): 999-1004.
[12] NMPA. Announcement of the state food and drug administration on the issuance of the technical guidelines for revision of safety information items in the instructions of traditional Chinese medicine on the market (trial)[EB/OL]. (2022-01-04) [2022-10-30]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20220107145808154.html.
[13] ZHANG B, WU H, ZHANG XM, et al.Clinical pharmacy service strategy based on the improvement of“warning words” in traditional Chinese patent medicines and simple preparations instructions[J]. Journal of Beijing University of Traditional Chinese Medicine(北京中医药大学学报), 2022, 45(10): 979-984.
[14] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China: Vdume I(中华人民共和国药典一部)[M]. Beijing: China Medical Science and Technology Press, 2020.
[15] Chinese Pharmacopoeia Commission.Clinical medication instructions in the pharmacopoeia of the People’s Republic of China traditional Chinese medicine formulation volume 2015 edition(中华人民共和国药典临床用药须知中药成方制剂卷2015版)[M]. Beijing: China Medical Science and Technology Press, 2015.
[16] National Essential Drug Clinical Application Guidelines and Prescription Compilation Committee. National Guidelines for Clinical Application of Essential Drugs(Traditional Chinese patent medicines and simple preparations roll), 2018 Edition(国家基本药物临床应用指南中成药2018年版)[M]. Beijing: People’s Medical Publishing House, 2018.
[17] National Essential Drug Prescription Compilation Committee. National Essential Drug Prescription Collection ,2009 Edition(国家基本药物处方集2009年版)[M].Beijing: People’s Medical Publishing House, 2009.
[18] ARONSON JK .Meyler’s Side Effects of Drugs(药物副作用)[M]. Beijing: Science Press(科学出版社), 2007.
[19] RAY SD.Side Effects of Drugs Annual(射线药物副作用年度报告)[M]. Amsterdam: Elsevier, 2018.
[20] ZHANG B, SA RN, ZHANG XM, et al.Research progress in pharmacogenic cardiotoxicity[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(8): 841-847.
[21] CAI H, ZHANG GQ.Analysis of the clinical use and irrational use of oral traditional Chinese patent medicines and simple preparations containing toxic traditional Chinese medicine ingredients in a hospital[J]. Anti-Infection Pharmacy(抗感染药学), 2022, 19(9): 1365-1368.